Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2004 Aug;63(8):940–944. doi: 10.1136/ard.2003.011734

Bone loss in patients treated with pulses of methylprednisolone is not negligible: a short term prospective observational study

G Haugeberg 1, B Griffiths 1, K Sokoll 1, P Emery 1
PMCID: PMC1755089  PMID: 15249320

Abstract

Objective: To examine the influence of intravenous pulsed methylprednisolone (MP) on bone mass.

Methods: 38 patients (30 women) with various rheumatic disorders requiring intravenous MP pulse treatment were examined at baseline and after 6 months with dual energy x ray absorptiometry (DXA), measuring hip and lumbar spine bone mineral density (BMD). Demographic and clinical data were collected.

Results: Demographics showed: mean (SD) age 48.4 (16.3) years, body mass index 24.9 (5.1) kg/m2, and median (range) disease duration 3.2 (0.1–40.0) years. During follow up patients received a mean cumulative MP dose of 3.0 (1.6) g given as 5.7 (2.0) pulses over a median period of 5.7 (2.3–33.7) months. 34/38 (89%) patients were also pulsed with cyclophosphamide, 20 (53%) were taking oral corticosteroids, and 8 (21%) were using either bisphosphonates or oestrogen. At the end of the study mean BMD was reduced by –2.2% at the femoral neck, –1.1% at the total hip, and –1.0% at the spine L2-4. In subgroups BMD increased in patients treated with bisphosphonates or oestrogen (femoral neck +1.6%, total hip +3.2%, spine L2-4 +4.5%), whereas BMD decreased at all sites in patients not treated with antirersorptive treatment, both for users (femoral neck –4.4%, total hip –2.4%, spine L2-4 –2.1%) and non-users of concomitant oral prednisolone (femoral neck –1.7%, total hip –1.9%, spine L2-4 –2.6%).

Conclusion: Treatment with intravenous pulses of MP leads to a high rate of bone loss. Prevention of bone loss in these patients with bisphosphonates and oestrogens should be considered.

Full Text

The Full Text of this article is available as a PDF (109.7 KB).

Figure 1.

Figure 1

Open in a new tab

 Percentage BMD change during follow up (mean with 95% confidence interval) in all 38 patients treated with methylprednisolone (white column), in the following subgroups: 14 patients not treated with antiresorptive drugs nor additional oral corticosteroids (light grey column), 16 patients not treated with antiresorptive drugs but additional oral corticosteroids (dark grey column), and 8 patients treated with antiresorptive drugs (black column). ART includes hormone replacement therapy (HRT) or bisphosphonates. Values in the table below the figure are baseline BMD (SD) values and BMD change (Δ% BMD) with standard error of the mean (SEM) for the different treatment groups at the different measurement sites. The p values are from the overall ANOVA.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adachi J. D., Bensen W. G., Brown J., Hanley D., Hodsman A., Josse R., Kendler D. L., Lentle B., Olszynski W., Ste-Marie L. G. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med. 1997 Aug 7;337(6):382–387. doi: 10.1056/NEJM199708073370603. [DOI] [PubMed] [Google Scholar]
  2. Adachi J. D., Olszynski W. P., Hanley D. A., Hodsman A. B., Kendler D. L., Siminoski K. G., Brown J., Cowden E. A., Goltzman D., Ioannidis G. Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum. 2000 Feb;29(4):228–251. doi: 10.1016/s0049-0172(00)80011-6. [DOI] [PubMed] [Google Scholar]
  3. Adu D., Pall A., Luqmani R. A., Richards N. T., Howie A. J., Emery P., Michael J., Savage C. O., Bacon P. A. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM. 1997 Jun;90(6):401–409. doi: 10.1093/qjmed/90.6.401. [DOI] [PubMed] [Google Scholar]
  4. Bijlsma J. W., Duursma S. A., Huber-Bruning O. Bone metabolism during methylprednisolone pulse therapy in rheumatoid arthritis. Ann Rheum Dis. 1986 Sep;45(9):757–760. doi: 10.1136/ard.45.9.757. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cohen S., Levy R. M., Keller M., Boling E., Emkey R. D., Greenwald M., Zizic T. M., Wallach S., Sewell K. L., Lukert B. P. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 1999 Nov;42(11):2309–2318. doi: 10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K. [DOI] [PubMed] [Google Scholar]
  6. Cranney A., Welch V., Adachi J. D., Homik J., Shea B., Suarez-Almazor M. E., Tugwell P., Wells G. Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Cochrane Database Syst Rev. 2000;(2):CD001983–CD001983. doi: 10.1002/14651858.CD001983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dolan A. L., Moniz C., Dasgupta B., Li F., Mackintosh C., Todd P., Corrigall V., Panayi G. S. Effects of inflammation and treatment on bone turnover and bone mass in polymyalgia rheumatica. Arthritis Rheum. 1997 Nov;40(11):2022–2029. doi: 10.1002/art.1780401115. [DOI] [PubMed] [Google Scholar]
  8. Hall G. M., Spector T. D., Griffin A. J., Jawad A. S., Hall M. L., Doyle D. V. The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women. Arthritis Rheum. 1993 Nov;36(11):1510–1516. doi: 10.1002/art.1780361105. [DOI] [PubMed] [Google Scholar]
  9. Haugeberg G., Bie R., Bendvold A., Larsen A. S., Johnsen V. Primary vasculitis in a Norwegian community hospital: a retrospective study. Clin Rheumatol. 1998;17(5):364–368. doi: 10.1007/BF01450893. [DOI] [PubMed] [Google Scholar]
  10. Haugeberg G., Myklebust G., Dovland H., Mikkelsen B., Gran J. T. No permanent reduction in bone mineral density during treatment of polymyalgia rheumatica and temporal arteritis using low dose corticosteroids. Scand J Rheumatol. 2000;29(3):163–169. doi: 10.1080/030097400750002030. [DOI] [PubMed] [Google Scholar]
  11. Haugeberg G., Uhlig T., Falch J. A., Halse J. I., Kvien T. K. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum. 2000 Mar;43(3):522–530. doi: 10.1002/1529-0131(200003)43:3<522::AID-ANR7>3.0.CO;2-Y. [DOI] [PubMed] [Google Scholar]
  12. Haugeberg G., Uhlig T., Falch J. A., Halse J. I., Kvien T. K. Reduced bone mineral density in male rheumatoid arthritis patients: frequencies and associations with demographic and disease variables in ninety-four patients in the Oslo County Rheumatoid Arthritis Register. Arthritis Rheum. 2000 Dec;43(12):2776–2784. doi: 10.1002/1529-0131(200012)43:12<2776::AID-ANR18>3.0.CO;2-N. [DOI] [PubMed] [Google Scholar]
  13. Haugeberg Glenn, Ørstavik Ragnhild E., Uhlig Till, Falch Jan A., Halse Johan I., Kvien Tore K. Bone loss in patients with rheumatoid arthritis: results from a population-based cohort of 366 patients followed up for two years. Arthritis Rheum. 2002 Jul;46(7):1720–1728. doi: 10.1002/art.10408. [DOI] [PubMed] [Google Scholar]
  14. Homik J., Cranney A., Shea B., Tugwell P., Wells G., Adachi R., Suarez-Almazor M. Bisphosphonates for steroid induced osteoporosis. Cochrane Database Syst Rev. 2000;(2):CD001347–CD001347. doi: 10.1002/14651858.CD001347. [DOI] [PubMed] [Google Scholar]
  15. Homik J., Suarez-Almazor M. E., Shea B., Cranney A., Wells G., Tugwell P. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev. 2000;(2):CD000952–CD000952. doi: 10.1002/14651858.CD000952. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hutchinson R. M., Eastham R. D. A comparison of the erythrocyte sedimentation rate and plasma viscosity in detecting changes in plasma proteins. J Clin Pathol. 1977 Apr;30(4):345–349. doi: 10.1136/jcp.30.4.345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Illei G. G., Austin H. A., Crane M., Collins L., Gourley M. F., Yarboro C. H., Vaughan E. M., Kuroiwa T., Danning C. L., Steinberg A. D. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med. 2001 Aug 21;135(4):248–257. doi: 10.7326/0003-4819-135-4-200108210-00009. [DOI] [PubMed] [Google Scholar]
  18. Kvien Tore K., Mikkelsen Knut, Nordvåg Bjørn-Yngvar. Results from controlled clinical trials: how relevant for clinical practice? J Rheumatol. 2003 Jun;30(6):1135–1137. [PubMed] [Google Scholar]
  19. Lems W. F., Gerrits M. I., Jacobs J. W., van Vugt R. M., van Rijn H. J., Bijlsma J. W. Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 1996 May;55(5):288–293. doi: 10.1136/ard.55.5.288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Mier R. J. Prevention of corticosteroid induced osteoporosis. J Rheumatol. 1997 Feb;24(2):407–407. [PubMed] [Google Scholar]
  21. Pocock N. A., Eisman J. A., Dunstan C. R., Evans R. A., Thomas D. H., Huq N. L. Recovery from steroid-induced osteoporosis. Ann Intern Med. 1987 Sep;107(3):319–323. doi: 10.7326/0003-4819-107-2-319. [DOI] [PubMed] [Google Scholar]
  22. Saag K. G., Emkey R., Schnitzer T. J., Brown J. P., Hawkins F., Goemaere S., Thamsborg G., Liberman U. A., Delmas P. D., Malice M. P. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med. 1998 Jul 30;339(5):292–299. doi: 10.1056/NEJM199807303390502. [DOI] [PubMed] [Google Scholar]
  23. Sambrook P. N. Corticosteroid induced osteoporosis. J Rheumatol Suppl. 1996 Aug;45:19–22. [PubMed] [Google Scholar]
  24. Sambrook P., Lane N. E. Corticosteroid osteoporosis. Best Pract Res Clin Rheumatol. 2001 Jul;15(3):401–413. doi: 10.1053/berh.2001.0157. [DOI] [PubMed] [Google Scholar]
  25. Zuckerman E., Keren D., Rozenbaum M., Toubi E., Slobodin G., Tamir A., Naschitz J. E., Yeshurun D., Rosner I. Hepatitis C virus-related arthritis: characteristics and response to therapy with interferon alpha. Clin Exp Rheumatol. 2000 Sep-Oct;18(5):579–584. [PubMed] [Google Scholar]
  26. van der Veen M. J., Bijlsma J. W. Effects of different regimes of corticosteroid treatment on calcium and bone metabolism in rheumatoid arthritis. Clin Rheumatol. 1992 Sep;11(3):388–392. doi: 10.1007/BF02207199. [DOI] [PubMed] [Google Scholar]
  27. van der Veen M. J., Bijlsma J. W. The effect of methylprednisolone pulse therapy on methotrexate treatment of rheumatoid arthritis. Clin Rheumatol. 1993 Dec;12(4):500–505. doi: 10.1007/BF02231779. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES